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Tetanus is a neurological disorder caused by Clostridium tetani. Although 
vaccination has significantly reduced the incidence of tetanus worldwide, the 
occurrence of sporadic cases requires effective and timely treatment. In this study, 
we report the case of a 45-year-old man who had difficulty in swallowing and 
opening mouth. The patient had the history of a small puncture wound with a nail 
in his toes about 12 days ago.  
 Keywords:  Tetanus, Toxin, Muscle spasms, Clostridium tetani, Immunization 
 
 
Corresponding Information:  
Roghayeh Teimourpour, Dept. of Microbiology, School of Medicine, Ardabil 
University of Medical Sciences, Ardabil Iran E-Mail: r.teymourpour@gmail.com 
Received:  2020/04/16; 
Accepted: 2020/08/12; 
Published Online: 21 Oct 2020  
 





Copyright © 2020, This is an original open-access article distributed under the terms of the Creative Commons Attribution-noncommercial 4.0 International License which permits 
copy and redistribution of the material just in noncommercial usages with proper citation. 
 
Introduction
Clostridium tetani is an obligate anaerobic, gram-
positive, and spore-forming bacillus found globally in 
soil, intestinal tracts, and feces of different animals. In 
some cases, it may be present in the human 
gastrointestinal tract as a transient microflora. Tetanus 
toxin or tetanospasmin is the most important virulence 
factor of C. tetani that affects motor neurons causing 
tetanic convulsions. Tetanus is a life-threatening disease 
characterized by progressive muscle tension and spastic 
paralysis (1). 
According to the Centers for Disease Control and 
Prevention (CDC), between 70 and 35 new cases of 
tetanus are reported annually most of which are related 
to the elderly population (over 60 years), suggesting a 
reduction in the protective effect of the primary 
vaccination (2). Drug users are another high-risk group. 
In developing countries, the mortality rate is high 
(about 28,000 deaths per 100,000 populations) (2). 
Two-thirds of global tetanus cases occur in South 
Africa, in which more than 40% are due to neonatal 
infections (3). In most cases, tetanus occurs as a result 
of a serious injury, such as puncture, laceration, or 
scratching. In some cases, no damage can be detected 
and chronic conditions such as skin lesions, abscesses, 
and gangrene may be involved (4). Moreover, the 
relationship between tetanus and burns, frostbite, 
middle ear infections, surgery, abortion, childbirth, 
drug abuse, and tattooing has been reported. In rare 
cases, the source of infection and mode of transmission 
is unclear (5). C. tetani spores are very stable and 
resistant to environmental conditions, heat, and 
different antiseptics. Contamination of wounds with 
spores is common, but germination, growth, and 
production of the neurotoxin only occurs in wounds 
with low oxidation-reduction potential such as 
devitalized tissue, foreign bodies, or dirty wounds; this 
could facilitate the growth of anaerobic microbes. C. 
tetani is not able to induce inflammatory responses 
alone and the feature of infection remains benign at the 
portal of entry unless polymicrobial infection develops. 
In a contaminated wound, when vegetative cells lyse, 
toxin releases and spreads through the lymphatic 
system and blood, and then reaches the terminal of 
motor neurons. After the light chain of toxin enters the 
motor neuron travels to the neuron cell body at the 
spinal cord and brain stem in a retrograde manner. As 
a result, inhibitory neurotransmitters including gamma-
aminobutyric acid (GABA) and glycine are not 
released from central inhibitory neurons. These 
neurotransmitters have an inhibitory effect on motor 
neurons and in the absence of this central inhibition, 
hyperactivity, uncontrolled muscle spasms and spastic 
paralysis can be developed. The binding of the toxin to 
the neuron is irreversible and recovery of the neural 
function can be achieved by new nerve terminals 
sprouting and new synapses formation (6, 7). 
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A 45-year-old man with dysphasia and pain in the 
back of the head was admitted to the emergency 
department. The patient was unable to open his mouth. 
During the clinical examination, he was conscious and 
distressed, had hyperhidrosis, and uncontrollable 
laughing. At the time of hospital admission, the patient’s 
symptoms were BP=175/90, HR=145, RR=30, BT=37, 
and SO2=93% at room temperature. He had severe back 
pain when bending his legs and head and oral examination 
of the patient was not possible due to masseter muscle 
rigidity. He had no problem in upper limb function, and 
only a slight stiffness and tension was seen in the 
intercostal muscles. During lung auscultation, a reduction 
in lung sound intensity was detected. 
Tachycardia and abdominal wall muscle rigidity were 
remarkable, but there was not any sensitivity, 
tenderness, and organomegaly. The tibialis anterior 
muscle was normal while the deep muscles of the 
posterior leg were tight. Plantar reflexes were normal 
and the presence of a scar between the first and second 
toes of the left foot was clear, though no active infection 
was found. The results of computerized tomography 
scan (CT scan) were normal, and the patient was 
subjected to tetanus treatment. Tracheal tube and 
antispastic drugs were used for opening airways and 
treatment of spasticity, respectively. Tetanus vaccine in 
conjunction with tetabulin were injected into different 
muscles and then administration of metronidazole and 
heparin prophylaxis was started. Concerning excessive 
sweating, high blood pressures, and tachycardia, metoral 
was given. Despite the onset of midazolam and 
diazepam medication, muscle spasms were rising, and 
sometimes severe generalized spasms happened. On day 
3, with increasing masseter muscle spasm, the existing 
tracheal tube was replaced with a tracheostomy tube. 
Regarding the continuation of spasms, antispastic 
treatments were increased; but severe spasms of the 
Hamstring, back, neck, and intercostal muscles resulted 
in the addition of atracurium based on the 
recommendations of an anesthesiologist, and a ventilator 
was connected to the patient. In the following days, with 
continuing hyperhidrosis, hypertension (>200/90), heart 
rate (>156), and a gradual and significant increase in 
CPK and CK-MB, the patient received captopril and 
aspirin in combination with metoral based on 
recommendations made by a cardiologist.  
On day 8, when infusion dose of diazepam, 
midazolam, and atracurium reached to 12 mg/h, 20 
mg/h, and 40 mg/h, respectively, intense and frequency 
of muscle spasm attacks were confined; but in certain 
circumstance, such as suction of discharges, he 
experienced high blood pressure and heart rate 
occasionally. The patient experienced a high fever 
(>38.8°C) from the second day of hospitalization. 
Therefore, gavage feeding was started using a 
nasogastric tube. Due to anemia and low MCV and 
MCH, a hemoglobin test was performed, the results of 
which showed that the amount of HbA2 was about 4.6%. 
Table 1 shows the laboratory test results on different 
days of hospitalization. During the hospitalization, two 
packed red blood cells were transfused due to 
hemoglobin decline, and there was no evidence of 
melena in the patient's stool examination. Atracurium 
was gradually reduced from day 9, then discontinued 
within one week. 
By reducing muscle spasms, metronidazole 
completely discontinued on day 16 of hospitalization 
and the doses of diazepam and midazolam were 
gradually decreased so that on day 31, midazolam 
completely stopped and diazepam with a dose of 7 mg/h 
was continued. On day 40, the infusion of diazepam was 
stopped, and blood pressure, heart rate, and 
consciousness returned to normal conditions. Any 
obstruction and spasm of airways were checked by 
bronchoscopy and a tracheostomy tube was taken out on 
day 45. After physio consultation, physical therapy 
began. The patient was discharged from the ICU 
department with a good general condition on day 51. At 
that time, he had slight pain and swelling in the right 
knee, a significant reduction in weight, and needed 
support for walking.  
 
Table 1. Blood monitoring of the patient with tetanus during hospitalization 
 Day1 Day 4 Day7 Day10 Day12 Day21 Day31 Day48 
WBC 9700 8300 8000  6400 6400 6700 6300 
Hb 11.8 9.6 8.7  7.5 9.3 10 9.6 
Hct 40.2 32.2 28.8  25.8 30.6 31.8 30.8 
Plt 326000 211000 217000  296000 310000 342000 340000 
BUN 64 43 20   22 105 12 
Cr 1.1 1.1 0.8   0.7 0.8 0.8 
Ca 8.8 8.7  9.1  8.9 9.4 9.6 
P 3.2 2  3.2  5.7 4.2 4.4 
Na 148 148 140 137  132 132 140 
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 Day1 Day 4 Day7 Day10 Day12 Day21 Day31 Day48 
K 4.4 4.1 3.1 3.8  4.1 4.3 4.9 
LDH  2385 972 1182 591    
CPK 1420 801 769 386 165    
CK-MB 39 88 64 42 13    
 
Discussion 
C. tetani, as a causative agent of tetanus, is an 
anaerobic and spore-forming bacillus which is 
dispersed in the soil and environment. Neck stiffness, 
dysphagia, inability in opening the mouth, muscle 
rigidity, and painful spasms are the clinical features of 
tetanus disease. Since the eradication of C. tetani 
spores from the environment is not possible, active and 
passive immunization along with appropriate treatment 
of wounds and injuries are critical for tetanus 
prevention and management. 
The diagnosis of tetanus is entirely based on clinical 
findings. Laboratory tests cannot be used to completely 
confirm or reject infection, and isolation of C. tetani 
from the wound has not enough sensitivity and 
specificity. However,  gamma electromyography 
(EMG) may be useful (8-10). Several conditions, 
including alveolar abscesses, strychnine poisoning, 
drug-induced dystonia, and hypocalcemic tetany 
mimic tetanus, which must be differentiated from 
tetanus. Checking the precise vaccination history of 
individuals and possible traumas can be helpful in 
primary diagnosis and initiating appropriate treatment 
and preventive interventions (11, 12).  The goal of the 
treatment is to eliminate the source of the toxin, 
neutralize the free toxin, control muscle spasms, 
monitor the patient's condition, and provide the 
necessary care, especially respiratory care. These 
considerations should be followed until the recovery of 
the patient. Toxin neutralization and eradication of C. 
tetani in infected people can be achieved by specific 
anti-toxin antibodies and antibiotics like penicillin or 
metronidazole, respectively. As the antibody titer 
decreases with age, vaccine and antibody should be 
injected after any burns, perforations, and crush 
injuries (13). Also, airway obstruction is one the most 
important complications of tetanus; therefore, 
tracheostomy or placing tracheal tube is recommended 
to open the airway urgently (14). 
 
Conclusion  
Although the incidence of tetanus in Iran with a 
regular schedule of vaccination program is rare, it is 
still a lethal disease and remains an important cause of 
death among preventable diseases by vaccination. 
Elderly people and neonates are at-risk patients and 
need more attention in this regard. Therefore, 
differential and appropriate treatment in line with 
booster immunization should be considered in high-
risk groups presenting muscular rigidity (15). In 
summary, in this case report, a 45-year-old man with 
oropharyngeal and generalized signs was successfully 
treated with antispastic agents, tetabulin, vaccination, 
and antibacterial therapy. 
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